BioLife Solutions (BLFS) Leaps as Trials Meet Endpont

BioLife Solutions Inc (NASDAQ: BLFS) gained 68.2% to $3.33 as the company reported that its customer's TiGenix Phase 3 clinical trial has met primary endpoint. Share volume was one million, dwarfing an all-day average of 55,000